Sanara MedTech Q2 revenue rises on soft-tissue product growth
Sanara MedTech Q2 revenue rises on soft-tissue product growth
Overview
US surgical medtech firm's Q2 revenue rose 9% yr/yr to $28.1 mln
Company posted Q2 net loss from continuing operations, citing higher SG&A and interest expenses
Sanara to be acquired by MIMEDX in a deal pending customary closing conditions
Outlook
Sanara expects OsStic bone void filler to be introduced to the market in Q1 2027
Result Drivers
SOFT TISSUE PRODUCT GROWTH - Q2 revenue growth was driven by an 11% increase in sales of soft tissue repair products, including CellerateRX Surgical, BIASURGE and FORTIFY TRG
HIGHER SG&A AND INTEREST EXPENSES - Increased selling, general and administrative costs, along with higher interest expense, contributed to the Q2 net loss from continuing operations
LEGAL AND ADVISORY COSTS - Legal and advisory expenses related to corporate strategic initiatives, including the pending MIMEDX acquisition, raised operating costs
Company press release: ID:nGNX3qnfPZ
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| $28.1 mln | $28.95 mln (2 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Sanara Medtech Inc is $35.00, about 2.2% above its August 10 closing price of $34.25
The stock recently traded at 75 times the next 12-month earnings vs. a P/E of 56 three months ago
Reuters Recommended Reads
Aug 11 - Xtant Medical Q2 revenue falls on asset sales and lost license revenue
Aug 10 - TELA Bio Q2 revenue falls on lower OviTex PRS volumes, withdraws outlook
Aug 10 - Tactile Systems Q2 revenue up 9%, slightly beats estimates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)